As a PI3Kα selective inhibitor and mutant PI3Kα degrader, inavolisib can degrade mutant p110α protein without significantly altering wild-type p110α protein, so it can effectively improve the efficacy of PIK3CA mutant tumour patients.81 This evidence concerns the gene PIK3CA and neoplasm.